...
机译:从发起者incripixImab切换后生物纤维单纤项(CT-P13)的长期疗效和安全性:NOR-Switch试验的开放标签延伸
Diakonhjemmet Hosp Dept Rheumatol Postbox 23 N-0319 Oslo Norway;
Akershus Univ Hosp Dept Gastroenterol Lorenskog Norway;
Diakonhjemmet Hosp Dept Rheumatol Postbox 23 N-0319 Oslo Norway;
Diakonhjemmet Hosp Dept Rheumatol Postbox 23 N-0319 Oslo Norway;
Radiumhosp Oslo Univ Hosp Dept Med Biochem Oslo Norway;
Diakonhjemmet Hosp Dept Rheumatol Postbox 23 N-0319 Oslo Norway;
Univ Oslo Inst Clin Med Oslo Norway;
Haukeland Hosp Dept Dermatol Bergen Norway;
Natl Hosp Norway Oslo Univ Hosp Dept Dermatol Oslo Norway;
Alesund Hosp Dept Gastroenterol Alesund Norway;
Haukeland Hosp Dept Rheumatol Bergen Norway;
Univ Hosp Northern Norway Dept Rheumatol Tromso Norway;
Sankt Olavs Hosp Dept Dermatol Trondheim Norway;
Radiumhosp Oslo Univ Hosp Dept Med Biochem Oslo Norway;
Radiumhosp Oslo Univ Hosp Dept Med Biochem Oslo Norway;
Gjovik Hosp Dept Gastroenterol Gjovik Norway;
Haugesund Hosp Dept Dermatol Haugesund Norway;
Haugesund Hosp Dept Gastroenterol Haugesund Norway;
Sankt Olavs Hosp Dept Gastroenterol Trondheim Norway;
Univ Hosp Northern Norway Dept Rheumatol Tromso Norway;
Sorlandet Hosp Dept Gastroenterol Kristiansand North Ireland;
Baerum Hosp Dept Gastroenterol Baerum North Ireland;
Helgelandssykehuset Dept Rheumatol Mo I Rana North Ireland;
Forde Hosp Dept Dermatol Forde North Ireland;
Telemark Hosp Dept Gastroenterol Skien Norway;
Ostfold Hosp Dept Gastroenterol Fredrikstad Norway;
Sorlandet Hosp Dept Rheumatol Kristiansand Norway;
Levanger Hosp Dept Rheumatol Levanger Norway;
Bodo Hosp Dept Rheumatol Bodo Norway;
Forde Hosp Dept Rheumatol Forde Norway;
Univ Oslo Inst Clin Med Oslo Norway;
Sorlandet Hosp Dept Gastroenterol Arendal Norway;
Kongsvinger Hosp Dept Rheumatol Kongsvinger Norway;
Lillehammer Hosp Dept Gastroenterol Lillehammer Norway;
Ostfold Hosp Dept Rheumatol Moss Norway;
Revmatismesykehuset Dept Rheumatol Lillehammer Norway;
Sankt Olavs Hosp Dept Dermatol Trondheim Norway;
Vestfold Hosp Dept Gastroenterol Tonsberg Norway;
Hamar Hosp Dept Gastroenterol Hamar Norway;
Elverum Hosp Dept Gastroenterol Elverum Norway;
Bodo Hosp Dept Gastroenterol Bodo Norway;
Betanien Hosp Dept Rheumatol Skien Norway;
Norges Psoriasis Og Eksemforbund Oslo Norway;
Landsforeningen Fordoyelsessykdommer Nes Norway;
Norsk Revmatikerforbund Oslo Norway;
Norwegian Univ Sci &
Technol Fac Med Inst Canc Res &
Mol Med Trondheim Norway;
Akershus Univ Hosp Dept Gastroenterol Lorenskog Norway;
Diakonhjemmet Hosp Dept Rheumatol Postbox 23 N-0319 Oslo Norway;
biosimilar; chronic inflammatory disease; drug costs; health economics; infliximab; switching;
机译:从发起者incripixImab切换后生物纤维单纤项(CT-P13)的长期疗效和安全性:NOR-Switch试验的开放标签延伸
机译:从发起者infliximab转换为生物仿制物CT-P13与发起者incriximab(NOR-SWITCH)的维护治疗相比:52周,随机,双盲,非劣势试验(Vol 389,PG 2304,2017)
机译:CT-P13(BioSimilarIngiximab)在类风湿性关节炎患者中的功效和安全性:从Planetra延伸研究中的CT-P13切换到CT-P13的切换与Planetra延伸研究中的持续CT-P13的比较
机译:创新者和生物纤维单纤维生素:宿主细胞蛋白和蛋白质高阶结构的可比性评估
机译:生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者:加拿大分析
机译:扩展报告:类风湿关节炎患者中CT-P13(生物仿制药英夫利昔单抗)的疗效和安全性:在PLANETRA扩展研究中从参考英夫利昔单抗转换为CT-P13与持续进行CT-P13之间的比较
机译:DOP062 BioSimilar Flowiximab(CT-P13)不逊于发起者Infliximab:来自Nor-Switch试验的Crohn病和溃疡性结肠炎的探索性IBD亚组分析